LY6 Gene Family: Potential Tumor Antigens and Prognostic Biomarkers in Endometrial Cancer


“Importantly, the expression of several LY6 genes is elevated in UCEC [uterine corpus endometrial carcinoma] when compared to the expression in normal uterine tissue.”


BUFFALO, NY- May 8, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Human LY6 gene family: potential tumor-associated antigens and biomarkers of prognosis in uterine corpus endometrial carcinoma.”


The human Lymphocyte antigen-6 (LY6) gene family has recently gained interest for its possible role in tumor progression. In this new study, researchers Luke A. Rathbun, Anthony M. Magliocco and Anil K. Bamezai from Villanova University carried out in silico analyses of all known LY6 gene expression and amplification in different cancers using TNMplot and cBioportal. In addition, the team analyzed patient survival by Kaplan-Meier plotter after mining the TCGA database. 


“We report that upregulated expression of many LY6 genes is associated with poor survival in uterine corpus endometrial carcinoma (UCEC) cancer patients.”


Importantly, the expression of several LY6 genes is elevated in UCEC when compared to the expression in normal uterine tissue. For example, LY6K expression is 8.25× higher in UCEC compared to normal uterine tissue, and this high expression is associated with poor survival with a hazard ratio of 2.42 (p-value = 0.0032). Therefore, some LY6 gene products may serve as tumor-associated antigens in UCEC, biomarkers for UCEC detection, and possibly targets for directing UCEC patient therapy. 


“Further analysis of tumor-specific expression of LY6 gene family members and LY6-triggered signaling pathways is needed to uncover the function of LY6 proteins and their ability to endow tumor survival and poor prognosis in UCEC patients.”


Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28409


Correspondence to: Anil K. Bamezai


Email: [email protected] 


Keywords: LY6 gene family, uterine cancer, tumor-associated antigen, patient survival, biomarker



About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.


To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:







Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact: [email protected].


Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)

Copyright © 2023 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC